Treatment of mycosis fungoides and Sézary syndrome

Czech version

Authors: J. Polívka
Authors‘ workplace: Ústav hematologie a krevní transfuze, Praha
Published in: Transfuze Hematol. dnes,28, 2022, No. 1, p. 17-26.
Category: Review/Educational Papers
doi: https://doi.org/10.48095/cctahd202217

Overview

The aim of this review article is to introduce the topic of cutaneous T-cell lymphomas – mycosis fungoides and Sézary syndrome and the current treatment options. Cutaneous T-cell lymphomas are a rare group of non-Hodgkin lymphomas. Mycosis fungoides and Sézary syndrome are the most common subtypes of cutaneous T-cell lymphomas. Advanced stages of mycosis fungoides and Sézary syndrome are burdened by significant morbidity, mortality and limited therapeutic options. In 2018, based on the phase 3 trial (MAVORIC) study, the FDA and EMA approved mogamulizumab for relapsed or refractory mycosis fungoides and Sézary syndrome pre-treated with at least one systemic therapy. Together with brentuximab vedotin and alemtuzumab, mogamulizumab represents a new effective systemic treatment for patients with mycosis fungoides and Sézary syndrome.

Keywords:

treatment – mycosis fungoides – Sézary syndrome – cutaneous T-cell lymphomas –mogamulizumab

Sources

1. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019; 133 (16): 1703–1714.

2. Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas – an update 2021. Hematol Oncol. 2021; 39: 46–51.

3. Agar NS, Wedgeworth E, Crichton E, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010; 28: 4730–4739.

4. de Coninck EC, Kim YH, Varghese A, et al. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol. 2001; 19: 779–784.

5. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003; 139: 857–866.

6. Dobos G, Pohrt A, Ram-Wolff C, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers 2020; 12: 2921.

7. Ettler J, Mužík J, Polívka J. Epidemiologie primárních kožních lymfomů v České republice podle dat Národního onkologického registru z let 2005–2015. Onkologie. 2018; 12 (3): 100–104.

8. Polivka J., Muzik J. Epidemiology of primary cutaneous lymphomas in the Czech Republic according to data of the Czech National Cancer Registry. Cutaneous lymphomas: insight & therapeutic progress, 13–15 October 2017, London.

9. Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010; 116: 767–771.

10. Horna P, Moscinski LC, Sokol L, et al. Naive/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: putative cell of origin overlaps disease classification. Cytometry B Clin. Cytom. 2019; 96B: 234–241.

11. Roelens M, Delord M, Ram-Wolff C, et al. Circulating and skin-derived Sezary cells: clonal but with phenotypic plasticity. Blood. 2017; 130: 1468–1471.

12. Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019; 181: 350–357.

13. Ram-Wolff C, Martin-Garcia N, Bensussan A, et al. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies. Am J Dermatopathol. 2010; 32 (8): 755–763.

14. Olsen EA, Whittaker S, Kim YH, et al. Clinical endpoints and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). J Clin Oncol. 2011; 29: 2598–2607.

15. Gibbs JD, Ma S, Kim A, et al. Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T-cell lymphoma. Oncol Rep. 2021; 45: 349–358.

16. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions of the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110: 1715–1722.

17. Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2021 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2021; 96 (10): 1313–1328.

18. Scarisbrick JJ, Prince H, Vermeer MH, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015; 33: 3766–3773.

19. Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013; 49: 2859–2868.

20. Scarisbrick JJ, Kim YH, Whittakeet SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol. 2014; 170 (6): 1226–1236.

21. Scarisbrick J, Quaglino P, Prince M et al. Prognostic factors in mycosis fungoides: the PROCLIPI study. In EORTC-CLTF Meeting on Cutaneous Lymphoma-Insights in Research and Catient Care. 2019; 119: S26–S26.

22. NCCN Guidelines. Primary Cutaneous Lymphomas. Version 2.2021 – March 4, 2021. [cit. 10. 11. 2021] Dostupné z: https: //www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf

23. Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29: iv30–iv40.

24. Wang Y, Bagot M. Updates in cutaneous lymphoma: evidence-based guidelines for the management of cutaneous lymphoma 2018. Br J Dermatol. 2019; 180: 443–444.

25. Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome – update 2017. Eur J Cancer. 2017; 77: 57–74.

26. Belada D, Trněný M, et al. Diagnostické a léčebné postupy u nemocných s maligními lymfomy – XI. vydání, KAP CZ, s. r. o., září 2020. ISBN 978-80-86780-61-0.

27. Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol. 2017; 28: 2517–2525.

28. Tarabadkar ES, Shinohara MM. Skin directed therapy in cutaneous T-cell lymphoma. Front Oncol. 2019; 9: 260.

29. Domingo-Domenech E, Duarte RF, Boumedil A, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021; 6: 1391–1401.

30. Wu XS, Lonsdorf AS, Hwang ST. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol. 2009; 129: 1115–1119.

31. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al. Circulating clonal CLA (þ) and CD4 (þ) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol. 2005; 152: 258–264.

32. Reneau JC, Wilcox RA. Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. Sem Hematol. 2021; 58: 103–113.

33. Larocca C, Kupper TS, LeBoeuf NR. Mogamulizumab forecast: clearer patients, with a slight chance of immune mayhem. Clin Cancer Res. 2019; 25 (24): 7272–7274.

34. Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamuli- zumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015; 125 (12): 1883–1889.

35. Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine recep- tor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014; 32 (11): 1157–1163.

36. Kasamon YL, Chen H, de Claro RA, et al. FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2019; 25: 7275–7280.

37. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphomas (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19 (9): 1192–11204.

38. Porcu P, Hudgens S, Horwit S, et al. Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2021; 21 (2): 97–105.

39. Zinzani PL, Horwitz SM, Kim YH, et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 MAVORIC study. Blood. 2018; 132: 1619.

40. Pro B, Kim YH, Ortiz Romero PL, et al. Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: a MAVORIC post hoc analysis. Hematol Oncol. 2019; 37 (15s): abstract 7539.

41. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235–242.

42. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377 (9759): 42–51.

43. Photiou L, van der Weyden C, McCormack C, Miles Prince H. Systemic treatment options for advanced-stage mycosis fungoides and Sézary syndrome. Curr Oncol Rep. 2018; 20 (4): 32.

44. Sethi, TK, Montanari F, Foss F, et al. How we treat advanced stage cutaneous T‐cell lymphoma–mycosis fungoides and Sézary syndrome. Brit J Haemat. 2021; 195 (3): 352–364.

45. Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sezary syndrome. Blood. 2016; 127 (25): 3142–3153.

46. Hughes CFM, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015; 125 (1): 71–81.

47. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017; 390: 555–566.

48. Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015; 33 (32): 3759–3765.

49. Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015; 33 (32): 3750–3758.

50. Stewart JR, Desai N, Rizvi S, et al. Alemtuzumab is an effective thirdline treatment versus single-agent gemcitabine or pralatrexate for refractory Sezary syndrome: a systematic review. Eur J Dermatol. 2018; 28 (6): 764–774.

51. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood. 2003; 101: 4267–4272.

52. deMasson A, Guitera P, Brice P, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014; 170 (3): 720–724.

53. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25 (21): 3109–3115.

54. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27 (32): 5410–5417.

55. Zinzani PL, Quaglino P, Violetti SA, et al. Critical concepts and management recommendations for cutaneous T‐cell lymphoma: A consensus‐based position paper from the Italian Group of Cutaneous Lymphoma. Hematol Oncol. 2021; 39 (3): 275–283.

56. Polívka J. Mogamulizumab: nová léčba pokročilých stádií kožních T buněčných lymfomů – mycosis fungoides a Sézaryho syndromu. Onkologie. 2021; 15 (4): 187–193.